PharmaNews.eu
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
| Page 1 of 122 | ||||||||||||||||||||||||||||||||||||||||||||||
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Eli Lilly and Company (NYSE: LLY) announced that its chemotherapy ALIMTA(R) (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE). Specifically, NICE's Final Appraisal Determination recommends ALIMTA as an option for the maintenance treatment of people with locally advanced or metastatic non-small cell lung cancer with other than predominantly squamous cell (nonsquamous) histology if disease has not progressed immediately following platinum-based chemotherapy first-line chemotherapy.
Novo Nordisk announced details of the company's cardiovascular outcomes trial for Victoza® (liraglutide) which is set to start in the autumn of 2010. The trial named LEADER™ (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) aims to assess and confirm the cardiovascular safety of the company's new once-daily human GLP-1 analogue Victoza® and potentially show the ability of Victoza® to improve cardiovascular outcomes. The trial also satisfies the new FDA guideline for type 2 diabetes treatments.
On 9 April the European Commission published two reports demonstrating the need for further progress in the European Union on the issue of anti microbial resistance. The first is a pan-European survey which reveals some worrying trends in public attitudes towards the use of antibiotics, while the second is a progress report on the 2002 Council Recommendation on the prudent use of antibiotics.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq® (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.
Sponsored Links
Diabetes PubMed
Latest Diabetes Research News and PubMed facts...
www.diabetespubmed.com
Latest Diabetes Research News and PubMed facts...
www.diabetespubmed.com
Global E-Health Forum 2010
25-26 October 2010, Hamburg, Germany.
www.global-ehealth-forum.com
Who's Online
We have 88 guests online
Industry News
Abbott | Amgen | AstraZeneca | Bayer | Boehringer Ingelheim | Bristol-Myers Squibb | Genzyme | GlaxoSmithKline | Lilly | Merck | Merck KGaA | Novartis | Novo Nordisk | Nycomed | Pfizer | Roche | Sanofi-aventis | Schering-Plough | Shire | ...Submit News
